Vestal Point Capital LP Raises Holdings in Savara Inc (NASDAQ:SVRA)

Vestal Point Capital LP increased its stake in shares of Savara Inc (NASDAQ:SVRA) by 24.7% during the 3rd quarter, Holdings Channel reports. The fund owned 8,090,000 shares of the company’s stock after purchasing an additional 1,600,000 shares during the quarter. Savara makes up about 2.6% of Vestal Point Capital LP’s investment portfolio, making the stock its 14th largest position. Vestal Point Capital LP’s holdings in Savara were worth $34,302,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of SVRA. Frazier Life Sciences Management L.P. grew its stake in shares of Savara by 103.9% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock worth $32,874,000 after purchasing an additional 4,157,385 shares during the period. Jennison Associates LLC boosted its holdings in Savara by 17.5% during the third quarter. Jennison Associates LLC now owns 6,732,776 shares of the company’s stock worth $28,547,000 after buying an additional 1,001,296 shares in the last quarter. Vanguard Group Inc. grew its position in Savara by 2.5% during the first quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock valued at $30,197,000 after buying an additional 148,673 shares during the period. Nantahala Capital Management LLC raised its position in shares of Savara by 198.2% in the second quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock worth $20,879,000 after acquiring an additional 3,443,541 shares during the period. Finally, Farallon Capital Management LLC boosted its stake in shares of Savara by 90.5% during the 2nd quarter. Farallon Capital Management LLC now owns 4,560,000 shares of the company’s stock worth $18,377,000 after acquiring an additional 2,165,701 shares in the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Joseph S. Mccracken acquired 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was purchased at an average price of $2.95 per share, with a total value of $59,000.00. Following the completion of the acquisition, the director now owns 210,837 shares of the company’s stock, valued at $621,969.15. This trade represents a 10.48 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 5.13% of the stock is currently owned by company insiders.

Savara Stock Performance

Shares of SVRA opened at $3.47 on Friday. Savara Inc has a 52-week low of $2.82 and a 52-week high of $5.70. The firm’s fifty day moving average is $3.68 and its two-hundred day moving average is $4.09. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, meeting analysts’ consensus estimates of ($0.11). Equities analysts predict that Savara Inc will post -0.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SVRA has been the subject of several recent analyst reports. Evercore ISI restated an “in-line” rating and issued a $5.00 price target (down previously from $7.00) on shares of Savara in a research note on Wednesday, November 13th. HC Wainwright cut their price objective on Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Finally, JMP Securities reiterated a “market outperform” rating and set a $9.00 target price on shares of Savara in a research report on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $10.17.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.